Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 23634965)

1.

Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease.

Chalermpalanupap T, Kinkead B, Hu WT, Kummer MP, Hammerschmidt T, Heneka MT, Weinshenker D, Levey AI.

Alzheimers Res Ther. 2013 Apr 29;5(2):21. doi: 10.1186/alzrt175. eCollection 2013. Review.

2.

Roles of sigma-1 receptors in Alzheimer's disease.

Jin JL, Fang M, Zhao YX, Liu XY.

Int J Clin Exp Med. 2015 Apr 15;8(4):4808-20. eCollection 2015. Review.

3.

Norepinephrine ignites local hot spots of neuronal excitation: How arousal amplifies selectivity in perception and memory.

Mather M, Clewett D, Sakaki M, Harley CW.

Behav Brain Sci. 2015 Jul 1:1-100. [Epub ahead of print]

PMID:
26126507
4.

Age-related neurodegeneration prevention through mTOR inhibition: potential mechanisms and remaining questions.

Jahrling JB, Laberge RM.

Curr Top Med Chem. 2015 Jun 10. [Epub ahead of print]

PMID:
26059360
5.

Pathophysiological Links Among Hypertension and Alzheimer's Disease.

Carnevale D, Perrotta M, Lembo G, Trimarco B.

High Blood Press Cardiovasc Prev. 2015 Jun 9. [Epub ahead of print]

PMID:
26054481
6.

Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer's disease.

De Felice FG, Lourenco MV.

Front Aging Neurosci. 2015 May 19;7:94. doi: 10.3389/fnagi.2015.00094. eCollection 2015. Review.

7.

Prevention strategies targeting different preclinical stages of Alzheimer's disease.

B Z.

Curr Alzheimer Res. 2015 May 30. [Epub ahead of print]

PMID:
26027809
8.

Assessment of potential targets for deep brain stimulation in patients with Alzheimer's disease.

Sharma M, Deogaonkar M, Rezai A.

J Clin Med Res. 2015 Jul;7(7):501-5. doi: 10.14740/jocmr2127w. Epub 2015 May 8. Review.

9.

Object recognition test for studying cognitive impairments in animal models of Alzheimer's disease.

Bengoetxea X, Rodriguez-Perdigon M, Ramirez MJ.

Front Biosci (Schol Ed). 2015 Jun 1;7:10-29.

PMID:
25961683
10.

Masitinib for the treatment of mild to moderate Alzheimer's disease.

Folch J, Petrov D, Ettcheto M, Pedrós I, Abad S, Beas-Zarate C, Lazarowski A, Marin M, Olloquequi J, Auladell C, Camins A.

Expert Rev Neurother. 2015 Jun;15(6):587-96. doi: 10.1586/14737175.2015.1045419. Epub 2015 May 11.

PMID:
25961655
11.

Advances in Alzheimer's disease drug development.

Rafii MS, Aisen PS.

BMC Med. 2015 Mar 25;13:62. doi: 10.1186/s12916-015-0297-4.

12.

Early neurone loss in Alzheimer's disease: cortical or subcortical?

Arendt T, Brückner MK, Morawski M, Jäger C, Gertz HJ.

Acta Neuropathol Commun. 2015 Feb 10;3:10. doi: 10.1186/s40478-015-0187-1.

13.

Stem cell therapy for Alzheimer's disease and related disorders: current status and future perspectives.

Tong LM, Fong H, Huang Y.

Exp Mol Med. 2015 Mar 13;47:e151. doi: 10.1038/emm.2014.124. Review.

14.

Animal models of regression/progression of kidney disease.

Lim BJ, Yang HC, Fogo AB.

Drug Discov Today Dis Models. 2014 Spring;11:45-51.

PMID:
25722733
15.

The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer's disease.

Joshi YB, Giannopoulos PF, Praticò D.

Trends Pharmacol Sci. 2015 Mar;36(3):181-6. doi: 10.1016/j.tips.2015.01.005. Epub 2015 Feb 20. Review.

PMID:
25708815
16.

Alzheimer's disease and type 2 diabetes: what is the connection?

Greene A, Ng J, Shepherd L, Carey K.

Consult Pharm. 2015;30(2):112-5. doi: 10.4140/TCP.n.2015.112.

PMID:
25695417
17.

Neurodegeneration: etiologies and new therapies.

Tan EK, Srivastava AK, Arnold WD, Singh MP, Zhang Y.

Biomed Res Int. 2015;2015:272630. doi: 10.1155/2015/272630. Epub 2015 Feb 3. No abstract available.

18.

Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.

Lista S, Dubois B, Hampel H.

J Nutr Health Aging. 2015 Feb;19(2):154-63. doi: 10.1007/s12603-014-0515-3.

PMID:
25651440
19.

Are inflammatory profiles the key to personalized Alzheimer's treatment?

Brothers HM, Wilcock DM.

Neurodegener Dis Manag. 2013;3(4):343-351.

20.

Reversing synapse loss in Alzheimer's disease: Rho-guanosine triphosphatases and insights from other brain disorders.

Lefort R.

Neurotherapeutics. 2015 Jan;12(1):19-28. doi: 10.1007/s13311-014-0328-4.

PMID:
25588580
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk